Fundamental Result Update

Aurobindo Pharma Q1FY20 Result Update



The company is confident of several new product launches and expects 40 incremental launches over next nine months. Going forward, revenue and earnings shall be driven by successful integration of Sandoz which is expected to happen in the near term. The company is investing in alternate formulations like respiratory inhalers, peptides, vaccines and depot injectables. We believe new product launches shall offset the normalized price erosion prevalent in the US markets. Further, recent developments pertaining to fire in Andhra plant leads to some risks pertaining to fresh USFDA inspections. Apart from this, the resolution to USFDA inspections in unit 3 which is a multi-product oral dosage form facility for non-cephalosporins and non-betalactams shall be a key driver in the medium term. At CMP of Rs 589, the stock is trading at 11.6x FY21E. We value the company at 13x FY21E and assign a HOLD rating to the stock with a revised target price of Rs 658 for an upside of 12%.


Tags: FundamentalResult Update


Search Reports

SEARCH

Reports

Daily Market Update...

Nifty opened higher traded...

Read More

Daily Market Update...

Nifty opened positive but...

Read More

Daily Market Update...

Nifty opened down and traded...

Read More

Daily Market Update...

Nifty opened positive but...

Read More

Daily Market Update...

Nifty opened down and traded...

Read More

Axis Bank Ltd Q3FY20 -...

Axis Bank Q3FY20 earnings...

Read More

LTTS

SHORT TERM TRADING CALL: BUY...

Read More

ICICI PRUDENTIAL

SHORT TERM TRADING CALL: BUY...

Read More

HDFC Bank Ltd. Q3FY20 -...

HDFC Bank’s performance...

Read More

Tata Consultancy...

TCS came out with reasonable...

Read More

Subscribe to newsletter

Request a call back

DISCLAIMER: Investment in markets is subject to market risk, the views and investment tips expressed by our research entity on arihantcapital.com are product of their own. Whilst meticulous care has been taken to ensure that the facts stated are accurate and opinions given are fair and reasonable, neither the analyst nor any employee of our company is in any way is responsible for its contents and nor is its accuracy or completeness guaranteed. ArihantCapital.com offers the views and opinions for assistance only and these are not intended and must not be alone taken as the basis for an investment decision. We advise the users to check with certified experts before taking any investment decisions. The investments discussed in this material may not be suitable for all investors. The recipient alone shall be fully responsible/are liable for any decision taken on the basis of this material.